Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

GENENTECH USA, INC.

Filed by AVENUE SOLUTIONS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 21, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
8beef190-c725-4044-ada1-b4c5f2cf1578
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; Medicare reimbursement for biosimilars

HCR · Health Issues

Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 340b drug pricing program; S. 891, Bipartisan Health Care Act H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)

Literal federal measure citations: S. 891, H.R. 1968

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.